Novo Nordisk - 42 Year Stock Price History | NVO

Historical daily share price chart and data for Novo Nordisk since 1982 adjusted for splits and dividends. The latest closing stock price for Novo Nordisk as of April 12, 2024 is 124.51.
  • The all-time high Novo Nordisk stock closing price was 134.95 on March 07, 2024.
  • The Novo Nordisk 52-week high stock price is 138.28, which is 11.1% above the current share price.
  • The Novo Nordisk 52-week low stock price is 75.56, which is 39.3% below the current share price.
  • The average Novo Nordisk stock price for the last 52 weeks is 98.55.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 119.3228 101.3779 134.9455 101.3779 124.5100 21.23%
2023 84.0039 67.1462 104.6939 64.8812 102.7083 54.79%
2022 53.4108 52.5461 66.3520 44.9677 66.3520 22.65%
2021 42.6120 33.8575 56.5502 31.7861 54.0965 63.39%
2020 30.4984 27.0728 34.9809 22.9442 33.1086 23.31%
2019 23.6092 21.5184 27.0264 21.3206 26.8502 26.73%
2018 21.9775 24.2642 26.0473 19.1039 21.1873 -11.88%
2017 19.0119 15.6104 24.0715 14.3327 24.0447 54.29%
2016 20.8802 24.2359 24.7515 13.7199 15.5843 -36.56%
2015 22.6286 17.7037 25.4752 17.4579 24.5658 39.32%
2014 18.4223 15.0164 20.4286 15.0164 17.6329 16.69%
2013 13.9144 13.3036 15.5829 12.3126 15.1105 15.44%
2012 11.7689 9.2177 13.6429 9.0995 13.0895 44.10%
2011 9.0860 8.6356 10.3581 7.4539 9.0838 3.90%
2010 6.6634 5.0080 8.7428 4.9096 8.7428 79.47%
2009 4.2780 3.9415 5.2895 3.2021 4.8714 27.03%
2008 4.4808 4.7004 5.4496 3.2849 3.8348 -19.75%
2007 3.9099 3.0305 5.0135 2.9866 4.7785 57.36%
2006 2.4346 2.0329 3.0628 1.9611 3.0367 51.05%
2005 1.8956 1.8656 2.1390 1.7325 2.0104 5.26%
2004 1.7284 1.4286 1.9364 1.3576 1.9100 34.61%
2003 1.2049 1.0027 1.4189 0.8646 1.4189 43.96%
2002 1.0789 1.3546 1.3847 0.7609 0.9856 -27.24%
2001 1.3592 1.1922 1.5616 1.1721 1.3546 14.19%
2000 1.1511 0.8955 1.5094 0.8248 1.1863 37.85%
1999 0.7714 0.9228 0.9228 0.6380 0.8606 -2.00%
1998 0.9250 0.9373 1.1176 0.7148 0.8782 -7.45%
1997 0.7051 0.5892 0.9505 0.5761 0.9489 55.02%
1996 0.4838 0.4558 0.6202 0.4150 0.6121 37.24%
1995 0.3612 0.3021 0.4460 0.2924 0.4460 45.32%
1994 0.3221 0.3183 0.3554 0.2843 0.3069 -3.58%
1993 0.2865 0.2820 0.3183 0.2508 0.3183 12.24%
1992 0.2812 0.2881 0.3075 0.2539 0.2836 -0.18%
1991 0.2225 0.1960 0.2936 0.1795 0.2841 44.65%
1990 0.1620 0.1548 0.2020 0.1389 0.1964 25.90%
1989 0.1370 0.1193 0.1618 0.1193 0.1560 30.76%
1988 0.0997 0.0699 0.1285 0.0699 0.1193 84.67%
1987 0.1011 0.0991 0.1252 0.0608 0.0646 -34.28%
1986 0.0920 0.0859 0.1029 0.0788 0.0983 12.99%
1985 0.0833 0.0703 0.1029 0.0685 0.0870 23.76%
1984 0.1238 0.1677 0.1810 0.0637 0.0703 -57.60%
1983 0.1733 0.1255 0.2154 0.1255 0.1658 27.64%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $558.743B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.181B 118.93
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.455B 83.83
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53